APO Research
Talk to an analyst

APO RESEARCH · REPORT

Daptomycin

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Daptomycin Market Outlook and Growth Opportunities 2026

20 December 2025193 pages

Choose your research edition.

Industry ResearchDaptomycin Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Daptomycin Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Daptomycin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Daptomycin Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Daptomycin Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Daptomycin market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Daptomycin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Daptomycin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Daptomycin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Daptomycin market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Daptomycin market include HENGRUI PHARMA, Hisun, Sagent Pharmaceuticals, Xellia, Fresenius Kabi, Huadong Medicine, Pfizer, Mylan and Merck & Co., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Daptomycin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Daptomycin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Daptomycin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Daptomycin market size, projected growth trends, production technologies, key applications, and end-use industries.

Daptomycin Segment by Company

HENGRUI PHARMA

Hisun

Sagent Pharmaceuticals

Xellia

Fresenius Kabi

Huadong Medicine

Pfizer

Mylan

Merck & Co.

Teva

Daptomycin Segment by Type

350 mg Lyophilized Powder

500 mg Lyophilized Powder

Daptomycin Segment by Application

Adult

Pediatric Patients (1 to 17 years of age)

Daptomycin Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Daptomycin status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Daptomycin market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Daptomycin significant trends, drivers, influence factors in global and regions.

6. To analyze Daptomycin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Daptomycin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Daptomycin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Daptomycin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Daptomycin market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Daptomycin industry.

Chapter 3: Detailed analysis of Daptomycin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Daptomycin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Daptomycin in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Daptomycin Industry Trends Table 2. Daptomycin Industry Drivers Table 3. Daptomycin Industry Opportunities and Challenges Table 4. Daptomycin Industry Restraints Table 5. Global Daptomycin Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Daptomycin Revenue Share by Company (2021-2026) Table 7. Global Daptomycin Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Daptomycin Sales Volume Share by Company (2021-2026) Table 9. Global Daptomycin Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Daptomycin Company Ranking, (2024-2026) & (USD Million) Table 11. Global Daptomycin Key Company Manufacturing Base & Headquarters Table 12. Global Daptomycin Company, Product Type & Application Table 13. Global Daptomycin Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Daptomycin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 350 mg Lyophilized Powder Table 18. Significant Companies of 500 mg Lyophilized Powder Table 19. Global Daptomycin Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 20. Global Daptomycin Sales Volume by Type (2021-2026) & (W Units) Table 21. Global Daptomycin Sales Volume by Type (2027-2032) & (W Units) Table 22. Global Daptomycin Sales Volume Share by Type (2021-2026) Table 23. Global Daptomycin Sales Volume Share by Type (2027-2032) Table 24. Global Daptomycin Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Daptomycin Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Daptomycin Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Daptomycin Sales Value Share by Type (2021-2026) Table 28. Global Daptomycin Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Adult Table 30. Significant Companies of Pediatric Patients (1 to 17 years of age) Table 31. Global Daptomycin Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 32. Global Daptomycin Sales Volume by Application (2021-2026) & (W Units) Table 33. Global Daptomycin Sales Volume by Application (2027-2032) & (W Units) Table 34. Global Daptomycin Sales Volume Share by Application (2021-2026) Table 35. Global Daptomycin Sales Volume Share by Application (2027-2032) Table 36. Global Daptomycin Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Daptomycin Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Daptomycin Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Daptomycin Sales Value Share by Application (2021-2026) Table 40. Global Daptomycin Sales Value Share by Application (2027-2032) Table 41. Global Daptomycin Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 42. Global Daptomycin Sales by Region (2021-2026) & (W Units) Table 43. Global Daptomycin Sales Market Share by Region (2021-2026) Table 44. Global Daptomycin Sales by Region (2027-2032) & (W Units) Table 45. Global Daptomycin Sales Market Share by Region (2027-2032) Table 46. Global Daptomycin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Daptomycin Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Daptomycin Sales Value Share by Region (2021-2026) Table 49. Global Daptomycin Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Daptomycin Sales Value Share by Region (2027-2032) Table 51. Global Daptomycin Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Daptomycin Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Daptomycin Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 54. Global Daptomycin Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Daptomycin Sales by Country (2021-2026) & (W Units) Table 56. Global Daptomycin Sales Market Share by Country (2021-2026) Table 57. Global Daptomycin Sales by Country (2027-2032) & (W Units) Table 58. Global Daptomycin Sales Market Share by Country (2027-2032) Table 59. Global Daptomycin Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Daptomycin Sales Value Market Share by Country (2021-2026) Table 61. Global Daptomycin Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Daptomycin Sales Value Market Share by Country (2027-2032) Table 63. HENGRUI PHARMA Company Information Table 64. HENGRUI PHARMA Business Overview Table 65. HENGRUI PHARMA Daptomycin Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. HENGRUI PHARMA Daptomycin Product Portfolio Table 67. HENGRUI PHARMA Recent Development Table 68. Hisun Company Information Table 69. Hisun Business Overview Table 70. Hisun Daptomycin Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Hisun Daptomycin Product Portfolio Table 72. Hisun Recent Development Table 73. Sagent Pharmaceuticals Company Information Table 74. Sagent Pharmaceuticals Business Overview Table 75. Sagent Pharmaceuticals Daptomycin Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Sagent Pharmaceuticals Daptomycin Product Portfolio Table 77. Sagent Pharmaceuticals Recent Development Table 78. Xellia Company Information Table 79. Xellia Business Overview Table 80. Xellia Daptomycin Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Xellia Daptomycin Product Portfolio Table 82. Xellia Recent Development Table 83. Fresenius Kabi Company Information Table 84. Fresenius Kabi Business Overview Table 85. Fresenius Kabi Daptomycin Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Fresenius Kabi Daptomycin Product Portfolio Table 87. Fresenius Kabi Recent Development Table 88. Huadong Medicine Company Information Table 89. Huadong Medicine Business Overview Table 90. Huadong Medicine Daptomycin Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Huadong Medicine Daptomycin Product Portfolio Table 92. Huadong Medicine Recent Development Table 93. Pfizer Company Information Table 94. Pfizer Business Overview Table 95. Pfizer Daptomycin Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Pfizer Daptomycin Product Portfolio Table 97. Pfizer Recent Development Table 98. Mylan Company Information Table 99. Mylan Business Overview Table 100. Mylan Daptomycin Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Mylan Daptomycin Product Portfolio Table 102. Mylan Recent Development Table 103. Merck & Co. Company Information Table 104. Merck & Co. Business Overview Table 105. Merck & Co. Daptomycin Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Merck & Co. Daptomycin Product Portfolio Table 107. Merck & Co. Recent Development Table 108. Teva Company Information Table 109. Teva Business Overview Table 110. Teva Daptomycin Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Teva Daptomycin Product Portfolio Table 112. Teva Recent Development Table 113. Key Raw Materials Table 114. Raw Materials Key Suppliers Table 115. Daptomycin Distributors List Table 116. Daptomycin Customers List Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Daptomycin Product Image Figure 2. Global Daptomycin Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Daptomycin Sales Value (2021-2032) & (US$ Million) Figure 4. Global Daptomycin Sales (2021-2032) & (W Units) Figure 5. Global Daptomycin Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Daptomycin Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 350 mg Lyophilized Powder Image Figure 10. 500 mg Lyophilized Powder Image Figure 11. Global Daptomycin Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 12. Global Daptomycin Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Daptomycin Sales Volume Share by Type (2021-2032) Figure 14. Global Daptomycin Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Daptomycin Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Daptomycin Sales Value Share by Type (2021-2032) Figure 17. Adult Image Figure 18. Pediatric Patients (1 to 17 years of age) Image Figure 19. Global Daptomycin Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 20. Global Daptomycin Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Daptomycin Sales Volume Share by Application (2021-2032) Figure 22. Global Daptomycin Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Daptomycin Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Daptomycin Sales Value Share by Application (2021-2032) Figure 25. Global Daptomycin Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 26. Global Daptomycin Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Daptomycin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Daptomycin Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Daptomycin Sales Value (2021-2032) & (US$ Million) Figure 30. North America Daptomycin Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Daptomycin Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Daptomycin Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Daptomycin Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Daptomycin Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Daptomycin Sales Value (2021-2032) & (US$ Million) Figure 36. South America Daptomycin Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Daptomycin Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Daptomycin Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Daptomycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Daptomycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Daptomycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Daptomycin Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Daptomycin Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • 350 mg Lyophilized Powder
  • 500 mg Lyophilized Powder
Applications
  • Adult
  • Pediatric Patients (1 to 17 years of age)
Companies covered
  • HENGRUI PHARMA
  • Hisun
  • Sagent Pharmaceuticals
  • Xellia
  • Fresenius Kabi
  • Huadong Medicine
  • Pfizer
  • Mylan
  • Merck & Co.
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Daptomycin Sales Value (2021-2032)
  4. 1.2.2 Global Daptomycin Sales Volume (2021-2032)
  5. 1.2.3 Global Daptomycin Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Daptomycin Market Dynamics
  1. 2.1 Daptomycin Industry Trends
  2. 2.2 Daptomycin Industry Drivers
  3. 2.3 Daptomycin Industry Opportunities and Challenges
  4. 2.4 Daptomycin Industry Restraints
3 Daptomycin Market by Company
  1. 3.1 Global Daptomycin Company Revenue Ranking in 2025
  2. 3.2 Global Daptomycin Revenue by Company (2021-2026)
  3. 3.3 Global Daptomycin Sales Volume by Company (2021-2026)
  4. 3.4 Global Daptomycin Average Price by Company (2021-2026)
  5. 3.5 Global Daptomycin Company Ranking (2024-2026)
  6. 3.6 Global Daptomycin Company Manufacturing Base and Headquarters
  7. 3.7 Global Daptomycin Company Product Type and Application
  8. 3.8 Global Daptomycin Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Daptomycin Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Daptomycin Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Daptomycin Market by Type
  1. 4.1 Daptomycin Type Introduction
  2. 4.1.1 350 mg Lyophilized Powder
  3. 4.1.2 500 mg Lyophilized Powder
  4. 4.2 Global Daptomycin Sales Volume by Type
  5. 4.2.1 Global Daptomycin Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Daptomycin Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Daptomycin Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Daptomycin Sales Value by Type
  9. 4.3.1 Global Daptomycin Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Daptomycin Sales Value by Type (2021-2032)
  11. 4.3.3 Global Daptomycin Sales Value Share by Type (2021-2032)
5 Daptomycin Market by Application
  1. 5.1 Daptomycin Application Introduction
  2. 5.1.1 Adult
  3. 5.1.2 Pediatric Patients (1 to 17 years of age)
  4. 5.2 Global Daptomycin Sales Volume by Application
  5. 5.2.1 Global Daptomycin Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Daptomycin Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Daptomycin Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Daptomycin Sales Value by Application
  9. 5.3.1 Global Daptomycin Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Daptomycin Sales Value by Application (2021-2032)
  11. 5.3.3 Global Daptomycin Sales Value Share by Application (2021-2032)
6 Daptomycin Regional Sales and Value Analysis
  1. 6.1 Global Daptomycin Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Daptomycin Sales by Region (2021-2032)
  3. 6.2.1 Global Daptomycin Sales by Region: 2021-2026
  4. 6.2.2 Global Daptomycin Sales by Region (2027-2032)
  5. 6.3 Global Daptomycin Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Daptomycin Sales Value by Region (2021-2032)
  7. 6.4.1 Global Daptomycin Sales Value by Region: 2021-2026
  8. 6.4.2 Global Daptomycin Sales Value by Region (2027-2032)
  9. 6.5 Global Daptomycin Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Daptomycin Sales Value (2021-2032)
  12. 6.6.2 North America Daptomycin Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Daptomycin Sales Value (2021-2032)
  15. 6.7.2 Europe Daptomycin Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Daptomycin Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Daptomycin Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Daptomycin Sales Value (2021-2032)
  21. 6.9.2 South America Daptomycin Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Daptomycin Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Daptomycin Sales Value Share by Country, 2025 VS 2032
7 Daptomycin Country-level Sales and Value Analysis
  1. 7.1 Global Daptomycin Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Daptomycin Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Daptomycin Sales by Country (2021-2032)
  4. 7.3.1 Global Daptomycin Sales by Country (2021-2026)
  5. 7.3.2 Global Daptomycin Sales by Country (2027-2032)
  6. 7.4 Global Daptomycin Sales Value by Country (2021-2032)
  7. 7.4.1 Global Daptomycin Sales Value by Country (2021-2026)
  8. 7.4.2 Global Daptomycin Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Daptomycin Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Daptomycin Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Daptomycin Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Daptomycin Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Daptomycin Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Daptomycin Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Daptomycin Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Daptomycin Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Daptomycin Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Daptomycin Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Daptomycin Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Daptomycin Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Daptomycin Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Daptomycin Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Daptomycin Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Daptomycin Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Daptomycin Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Daptomycin Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Daptomycin Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Daptomycin Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Daptomycin Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Daptomycin Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Daptomycin Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Daptomycin Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Daptomycin Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Daptomycin Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Daptomycin Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Daptomycin Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Daptomycin Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Daptomycin Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Daptomycin Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Daptomycin Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Daptomycin Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Daptomycin Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Daptomycin Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Daptomycin Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Daptomycin Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Daptomycin Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Daptomycin Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Daptomycin Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Daptomycin Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Daptomycin Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Daptomycin Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Daptomycin Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Daptomycin Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Daptomycin Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Daptomycin Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Daptomycin Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Daptomycin Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Daptomycin Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Daptomycin Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Daptomycin Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Daptomycin Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Daptomycin Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Daptomycin Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Daptomycin Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Daptomycin Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Daptomycin Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Daptomycin Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Daptomycin Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Daptomycin Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Daptomycin Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Daptomycin Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Daptomycin Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Daptomycin Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Daptomycin Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Daptomycin Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Daptomycin Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Daptomycin Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Daptomycin Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Daptomycin Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Daptomycin Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Daptomycin Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Daptomycin Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Daptomycin Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Daptomycin Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Daptomycin Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Daptomycin Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Daptomycin Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Daptomycin Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Daptomycin Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Daptomycin Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Daptomycin Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Daptomycin Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 HENGRUI PHARMA
  2. 8.1.1 HENGRUI PHARMA Company Information
  3. 8.1.2 HENGRUI PHARMA Business Overview
  4. 8.1.3 HENGRUI PHARMA Daptomycin Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 HENGRUI PHARMA Daptomycin Product Portfolio
  6. 8.1.5 HENGRUI PHARMA Recent Developments
  7. 8.2 Hisun
  8. 8.2.1 Hisun Company Information
  9. 8.2.2 Hisun Business Overview
  10. 8.2.3 Hisun Daptomycin Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Hisun Daptomycin Product Portfolio
  12. 8.2.5 Hisun Recent Developments
  13. 8.3 Sagent Pharmaceuticals
  14. 8.3.1 Sagent Pharmaceuticals Company Information
  15. 8.3.2 Sagent Pharmaceuticals Business Overview
  16. 8.3.3 Sagent Pharmaceuticals Daptomycin Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sagent Pharmaceuticals Daptomycin Product Portfolio
  18. 8.3.5 Sagent Pharmaceuticals Recent Developments
  19. 8.4 Xellia
  20. 8.4.1 Xellia Company Information
  21. 8.4.2 Xellia Business Overview
  22. 8.4.3 Xellia Daptomycin Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Xellia Daptomycin Product Portfolio
  24. 8.4.5 Xellia Recent Developments
  25. 8.5 Fresenius Kabi
  26. 8.5.1 Fresenius Kabi Company Information
  27. 8.5.2 Fresenius Kabi Business Overview
  28. 8.5.3 Fresenius Kabi Daptomycin Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Fresenius Kabi Daptomycin Product Portfolio
  30. 8.5.5 Fresenius Kabi Recent Developments
  31. 8.6 Huadong Medicine
  32. 8.6.1 Huadong Medicine Company Information
  33. 8.6.2 Huadong Medicine Business Overview
  34. 8.6.3 Huadong Medicine Daptomycin Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Huadong Medicine Daptomycin Product Portfolio
  36. 8.6.5 Huadong Medicine Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Daptomycin Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Daptomycin Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Mylan
  44. 8.8.1 Mylan Company Information
  45. 8.8.2 Mylan Business Overview
  46. 8.8.3 Mylan Daptomycin Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Mylan Daptomycin Product Portfolio
  48. 8.8.5 Mylan Recent Developments
  49. 8.9 Merck & Co.
  50. 8.9.1 Merck & Co. Company Information
  51. 8.9.2 Merck & Co. Business Overview
  52. 8.9.3 Merck & Co. Daptomycin Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Merck & Co. Daptomycin Product Portfolio
  54. 8.9.5 Merck & Co. Recent Developments
  55. 8.10 Teva
  56. 8.10.1 Teva Company Information
  57. 8.10.2 Teva Business Overview
  58. 8.10.3 Teva Daptomycin Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Teva Daptomycin Product Portfolio
  60. 8.10.5 Teva Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Daptomycin Value Chain Analysis
  2. 9.1.1 Daptomycin Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Daptomycin Sales Mode & Process
  6. 9.2 Daptomycin Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Daptomycin Distributors
  9. 9.2.3 Daptomycin Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst